中国全科医学 ›› 2027, Vol. 30 ›› Issue (01): 8-14.DOI: 10.12114/j.issn.1007-9572.2026.0299

• 标准·方案·指南 • 上一篇    

《中国心血管健康与疾病报告2025》要点解读

刘明波, 王增武*()   

  1. 100037 北京市,国家心血管病中心 中国医学科学院阜外医院
  • 收稿日期:2026-09-02 修回日期:2026-10-16 出版日期:2027-01-05 发布日期:2026-11-17
  • 通讯作者: 王增武

  • 作者贡献:

    刘明波进行文章框架设计与构思,论文撰写与修订;王增武进行论文审阅与修订;两位作者均阅读并同意最终稿件。

Highlights of Report on Cardiovascular Health and Diseases in China 2025

LIU Mingbo, WANG Zengwu*()   

  1. National Center for Cardiovascular Diseases/Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing 100037, China
  • Received:2026-09-02 Revised:2026-10-16 Published:2027-01-05 Online:2026-11-17
  • Contact: WANG Zengwu

摘要: 本文对《中国心血管健康与疾病报告2025》的核心内容进行系统解读。文章汇总了我国心血管疾病(CVD)及其主要危险因素的流行病学现状,分析了CVD诊疗状况、基础与临床研究进展、器械研发动态及疾病经济负担。数据显示,CVD仍居我国城乡居民死因首位,农村死亡率持续高于城市,男性死亡率高于女性。高血压、血脂异常、糖尿病、超重肥胖等危险因素广泛流行,但知晓率、治疗率和控制率仍处于较低水平。在诊疗方面,冠状动脉粥样硬化性心脏病(CHD)介入治疗持续增长,经导管主动脉瓣置换术(TAVR)年手术量首次超过外科瓣膜置换术,心律失常消融及器械植入技术稳步发展。研究层面,我国CVD领域论文数量与质量呈"质效双升"态势,创新医疗器械审评占比虽有回落,但产业化趋势未改。卫生经济学分析表明,CVD住院总费用持续攀升,CHD占比最高,老年人群经济负担尤为突出。本文主要面向全科临床工作者,立足于全科医学视角,在梳理数据的同时重点提炼对社区CVD危险因素筛查、患者长期管理及双向转诊具有指导意义的关键信息与实践策略,以期为CVD防治策略制定和医疗卫生资源配置提供科学依据。

关键词: 心血管疾病, 流行病学, 疾病负担, 危险因素, 患病率, 死亡率, 康复, 基础研究, 医疗器械研发, 卫生经济学

Abstract:

This article provides a systematic highlights of the core contents of the Report on Cardiovascular Health and Diseases in China 2025. It summarizes the latest epidemiological data on cardiovascular diseases (CVD) and their major risk factors, and analyzes the current status of CVD diagnosis and treatment, progress in basic and clinical research, medical device development, and disease economic burden in China. Data show that CVD remains the leading cause of death among both urban and rural residents, with mortality rates persistently higher in rural areas than in urban areas, and higher in men than in women. Risk factors including hypertension, dyslipidemia, diabetes, and overweight/obesity are widely prevalent, while awareness, treatment, and control rates remain low. In terms of diagnosis and treatment, percutaneous coronary intervention continues to grow, the annual volume of transcatheter aortic valve replacement (TAVR) has surpassed that of surgical aortic valve replacement for the first time, and technologies for arrhythmia ablation and device implantation have advanced steadily. In research, publications in the cardiovascular field have shown significant improvement in both quantity and quality; although the proportion of innovative medical devices under regulatory review has declined somewhat, the trend toward industrialization remains unchanged. Health economic analyses indicate that total inpatient costs for CVD continue to rise, with coronary heart disease accounting for the largest share, and the elderly bearing a particularly heavy economic burden. This article is mainly targeted at general-practice clinicians. From the perspective of general practice, while summarizing the data, it focuses on extracting key information and practical strategies guiding community-based CVD risk-factor screening, long-term patient management and bidirectional referral, aiming to provide scientific evidence for the formulation of CVD prevention and treatment strategies and the allocation of medical and healthcare resources.

Key words: Cardiovascular diseases, Epidemiology, Burden of disease, Risk factors, Prevalence, Mortality, Rehabilitation, Basic research, Medical device development, Health economics